Galmed Pharmaceuticals annual ebitda
2017
2018
2019
2020
Galmed Pharmaceuticals EBITDA Growth & History (GLMD)
Galmed Pharmaceuticals's calculated EBITDA was −$30.2M for fiscal 2020.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | −$30.2M | −$7.8M | — |
| 2019 | 2019-12-31 | −$22.3M | −$12.0M | — |
| 2018 | 2018-12-31 | −$10.3M | $1.8M | — |
| 2017 | 2017-12-31 | −$12.1M | — | — |
Galmed Pharmaceuticals quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Galmed Pharmaceuticals ebitda trends
Across the available reported history, Galmed Pharmaceuticals's ebitda decreased from −$22.3M to −$30.2M, a change of −$7.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals filings at SEC.gov ↗